Scn1b-null mice have a severe neurological and cardiac phenotype. Human mutations in SCN1B result in epilepsy and cardiac arrhythmia. SCN1B is expressed as two developmentally regulated splice variants, ␤1 and ␤1B, that are each expressed in brain and heart in rodents and humans. Here, we studied the structure and function of ␤1B and investigated a novel human SCN1B epilepsy-related mutation (p.G257R) unique to ␤1B. We show that wild-type ␤1B is not a transmembrane protein, but a soluble protein expressed predominantly during embryonic development that promotes neurite outgrowth. Association of ␤1B with voltage-gated Na ϩ channels Na v 1.1 or Na v 1.3 is not detectable by immunoprecipitation and ␤1B does not affect Na v 1.3 cell surface expression as measured by [ 3 H]saxitoxin binding. However, ␤1B coexpression results in subtle alteration of Na v 1.3 currents in transfected cells, suggesting that ␤1B may modulate Na ϩ current in brain. Similar to the previously characterized p.R125C mutation, p.G257R results in intracellular retention of ␤1B, generating a functional null allele. In contrast, two other SCN1B mutations associated with epilepsy, p.C121W and p.R85H, are expressed at the cell surface. We propose that ␤1B p.G257R may contribute to epilepsy through a mechanism that includes intracellular retention resulting in aberrant neuronal pathfinding.
Introduction
SCN1B is essential for life. Deletion of Scn1b in mice results in epilepsy, ataxia, growth retardation, cardiac abnormalities, and death Lopez-Santiago et al., 2007) . Human mutations in SCN1B result in genetic epilepsy with febrile seizures plus (GEFSϩ) spectrum disorders Patino and Isom, 2010) , Brugada syndrome (Watanabe et al., 2008) , and atrial fibrillation (Watanabe et al., 2009) . Patients carrying two alleles of a SCN1B functional null mutation, p.R125C, have Dravet syndrome, a pediatric encephalopathy associated with mental retardation that is the most severe GEFSϩ spectrum disease (Patino et al., 2009) . SCN1B is expressed as two splice variants, ␤1 and ␤1B (originally called ␤1A) that includes a retained intron encoding a novel C terminus, stop codon, and polyadenylation site Qin et al., 2003) . Both ␤1 and ␤1B are expressed in human brain and heart. ␤1 functions in current modulation, channel expression and subcellular localization, cell-cell adhesion, cellular migration, and neurite outgrowth (Brackenbury et al., 2008a,b) . In contrast, little is known about the function of ␤1B. Because Scn1b-null mice lack both splice variants, some aspects of their phenotype may be due to the absence of ␤1B; however, this has not been investigated. Because all of the SCN1B epilepsy mutations thus far are located in the Ig domain region common to both variants (Patino et al., 2009) , ␤1B, as well as ␤1, is likely involved in human brain disease. Our goal here was to understand the structure and function of ␤1B and to investigate a novel human SCN1B mutation (p.G257R) located in the region unique to ␤1B. We demonstrate that ␤1B is not a transmembrane protein but is a soluble protein that functions as a ligand for ␤1-mediated neurite outgrowth. While all four ␤-subunit genes have a similar exon-intron structure, only SCN1B appears to encode variants generated by alternate splicing, with variants that include two different retained introns (Oh and Waxman, 1994 ; Dib-Hajj and Waxman, 1995; Kazen-Gillespie et al., 2000), suggesting complex gene regulation. ␤1B is expressed predominantly during embryonic brain devel-using Trizol (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized from the extracted RNA as described below and dilutions made over a range of 5-log. Diluted cDNA was then used to perform TaqMan Gene Expression Assays in a StepOnePlus Real-Time PCR System with TaqMan Gene Expression Master Mix (both from Applied Biosystems) according to the manufacturer's instructions. C T determinations were made with the StepOne software, version 2.0 (Applied Biosystems), and used to calculate the efficiency of each primer pair. There was no statistical difference between the efficiencies of both sets of primers. Six micrograms of each sample of human RNA were incubated with DNase I (Invitrogen) following the manufacturer's instructions. cDNA was then synthesized using the SuperScript FirstStrand System (Invitrogen) according to the instructions of the manufacturer. The final volume of cDNA was then divided in 2 (for the ␤1 and ␤1B assays, respectively) and used as template for the TaqMan Gene Expression Assay using the standard cycling program. At least five repeats for each RNA sample were obtained. C T values were then used to calculate mean C T and SD for each sample. From the mean C T values, 2 Ϫ⌬CT were calculated for every developmental stage and SD calculated as the square root((SD of ␤1 C T ) 2 ϩ (SD of ␤1B C T ) 2 ). In silico prediction of transmembrane domains and amino acid sequence alignment. Amino acid sequences of human ␤1 (NP_001028.1), human ␤1B (NP_950238.1), rat ␤1 (NP_058984.1), rat ␤1B (AAF25186.1), and mouse ␤1 (NP_035452.1) were obtained from NCBI. The N-terminal region of mouse ␤1/␤1B, encoded by the first three exons of Scn1b, was obtained by aligning the mouse ␤1 sequence with those of the human and rat and comparing the common region to mouse chromosome 7 (AC158993.2). The unique C-terminal region of mouse ␤1B was obtained by translating the third intron of mouse Scn1b in the chromosome 7 sequence. The mouse ␤1B amino acid sequence used for analysis was the composite of the resulting N-and C-terminal sequences. To predict transmembrane domains, ␤1 and ␤1B amino acid sequences were analyzed using the Goldman Engelman Steitz hydrophobicity scale, with a certain cutoff value of 1.0 and a putative cutoff value of 0.6, using TopPred software (http://mobyle.pasteur.fr/cgi-bin/portal.py?formϭtoppred; Institut Pasteur) (von Heijne, 1992; Claros and von Heijne, 1994) . Alignment of human, mouse, and rat ␤1 and ␤1B amino acid sequences was performed using CLUSTALW software at the Pôle Bioinformatique Lyonnais (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?pageϭnpsa_ clustalw.html), using default settings (Thompson et al., 1994) .
Expression vectors and site-directed mutagenesis. The plasmid ␤1V5 contains a C-terminal V5-His-epitope tag and has been described previously (Patino et al., 2009) . The cDNA for human ␤1B was amplified by PCR and ligated into pTRACER-CMV2 (Invitrogen) at the EcoRI restriction site. The p.G257R mutation was introduced by site-directed mutagenesis using the QuikChange II kit (Stratagene). V5-His epitope tags were added to the C termini of ␤1B and ␤1B p.G257R cDNAs using a PCR strategy followed by ligation into pcDNA3.1/V5-His TOPO TA (Invitrogen). ␤1V5 and ␤1BV5 cDNAs were subcloned into pcDNA3.1 Hygro (ϩ) to facilitate generation of stable cell lines. The p.R214Q, p.S248R, and p.R250T mutations were introduced into ␤1BV5 cDNA in pcDNA3.1/V5-His by site-directed mutagenesis using the QuikChange II kit. A similar strategy was used to introduce the p.C121W and p.R85H mutations into ␤1V5 cDNA in pcDNA3.1/V5-His. We previously described ␤1Fc, a recombinant, secreted molecule containing the ␤1 extracellular domain fused to the Fc region of human IgG1 (McEwen and . To generate a stable ␤1Fc-producing cell line, cDNA encoding the extracellular domain of rat Scn1b was ligated into pINFUSEhIgG1-Fc1 (Invitrogen). The integrity of all plasmids was confirmed by DNA sequencing at the University of Michigan DNA Sequencing Core. PCR primers and conditions for all reactions are available upon request. The cDNA for human Na v 1.5 corresponding to the hH1 polymorphism (GenBank accession number M77235) (Makielski et al., 2003) in pRc-CMV (Invitrogen) was provided by Dr. Al George (Division of Genetic Medicine and Vanderbilt Institute for Integrative Genomics, Vanderbilt University, Nashville, TN).
Cell lines. All cell lines were maintained at 37°C with 5% CO 2 . Chinese hamster lung 1610 cells stably transfected with Na v 1.5 (1610hNa v 1.5), ␤1V5, or ␤1BV5 were cultured in DMEM with low glucose, L-glutamine, and sodium pyruvate supplemented with 5% heat-inactivated fetal bovine serum (HI-FBS), 100 U plus 100 g/ml penicillin/streptomycin, 400 g/ml (2R,3S,4R,5R,6S)-5-amino-6- [(1 R,2S,3S,4 R,6S)-4,6-diamino-3-[(2 R,3R,4 R,5R )-3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl]oxy-2-hydroxycyclohexyl] oxy-2-(1-hydroxyethyl)oxane-3,4-diol (G418), and 0.25 g/ml Fungizone (all from Invitrogen). HEK-293 cells expressing human Na v 1.1 (GenBank accession number NP_008851.3; HEKhNa v 1.1) were obtained from GlaxoSmithKline under a materials transfer agreement and maintained in DMEM supplemented with 10% HI-FBS, 400 g/ml G418, 1% nonessential amino acids, 100 U plus 100 g/ml penicillin/streptomycin, and 0.25 g/ml Fungizone. Chinese hamster ovary cells stably expressing human Na v 1.3 (GenBank accession number NP_008853.3; CHOhNa v 1.3) were provided by Dr. David Ragsdale (Montreal Neurological Institute, Montreal, QC, Canada) and maintained in 1ϫ Iscove's modified Dulbecco's medium with L-glutamine and 25 mM HEPES, supplemented with 10% HI-FBS, 400 g/ml G418, 1% nonessential amino acids, 100 U plus 100 g/ml penicillin/ streptomycin, and 1% HT supplement (Invitrogen).
For transient transfection of HEKhNa v 1.1 cells (Fugene 6; Roche), 7.5 g of cDNA encoding ␤1V5 or ␤1BV5 were used. Twenty-four to 48 h later, cells were collected for experiments. To generate stable cell lines, 2.5 g of ␤-subunit cDNAs were transfected (Fugene 6), and 24 h later cells were passaged into fresh medium containing selective antibiotics: G418 (400 g/ml) for Na v 1.5 or V5-Histagged ␤-subunit cDNAs; Hygromycin (400 g/ml) for V5-His-tagged ␤-subunit cDNAs transfected into cell lines stably expressing ␣-subunits; Zeocin (400 g/ml) for wild-type or mutant ␤1B-subunit cDNAs in pTRACER-CMV2 or for the generation of the ␤1Fc cell line. Antibioticresistant colonies were isolated and characterized as described previously (Isom et al., 1995) . To confirm stable transfection of pTRACER-CMV2 vectors, cells were plated in eight-chamber polystyrene vessel tissue culture-treated glass slides (Falcon; BD Biosciences Discovery Labware), rinsed with 1ϫ PBS (Invitrogen), and fixed with 4% paraformaldehyde for 20 min at room temperature (RT). The slides were mounted on glass coverslips using Gel/Mount (Biomeda) and viewed using a Fluoview 500 confocal laser-scanning microscope (Olympus) with 100ϫ objective. Images (1024 ϫ 1024 pixels) were acquired with the Olympus Optical Fluoview software. To edit the figures for this study, images were exported to Adobe Photoshop CS3 Extended, version 10.0.1. Other than cropping, no other changes were made to the images.
Detection of ␤1V5 or ␤1BV5 by immunofluorescence. Cells expressing ␤1V5, ␤1Fc, ␤1BV5 alone, or hNav1.5 plus ␤1BV5 were used for immunofluorescent staining. Cells on glass coverslips or on eight-chamber slides were fixed briefly with 4% paraformaldehyde and washed 3 times with 0.05 M phosphate buffer (PB) before use. Cells were permeabilized for a minimum of 1 h in PBTGS (0.1 M PB, 0.3% Triton X-100, and 10% normal goat serum) and incubated overnight with primary antibodies diluted in PBTGS. The following day, cells were incubated for 2 h in goat anti-mouse secondary antibody coupled to Alexa 594 (Invitrogen) diluted in PBTGS. Alternately, some cells were incubated with Alexa 488-conjugated anti-human IgG, Fc␥ fragment antibody diluted in PBTGS for 2 h. Samples were washed three times with 0.1 M PB after each antibody step. Cells were incubated with DAPI for 20 min and washed again with 0.1 M PB. Samples were air-dried and mounted onto SuperFrost Plus slides using ProLong Gold antifade reagent with DAPI (Invitrogen). Digital images were collected using a Nikon A1R confocal microscope with Nikon NIS-Elements software located in the Department of Pharmacology, University of Michigan. Figure 1 . ␤1B is the predominant SCN1B splice variant during human fetal brain development. A, Reverse transcriptase-PCR using primers for ␤1 or ␤1B performed with total RNA as template from human embryonic frontal lobe (22 week gestation, lanes 1 and 2; or 36 week gestation, lanes 3 and 4), postnatal frontal lobe (lanes 5 and 6), or postnatal occipital lobe (lanes 7 and 8). Samples of total RNA from Scn1b-null mouse brain were analyzed in parallel as negative controls (lanes 9 and 10). The gel shown is representative of triplicate experimental repeats. Nucleic acid markers are shown in base pairs. The arrows indicate ␤1 and ␤1B bands. B, Quantitative PCR was performed with cDNAs generated from the RNA frontal lobe samples using the TaqMan assay as described in Materials and Methods. Ratios of ␤1 to ␤1B were compared using the 2 Ϫ⌬CT method for each time point. Values are presented as mean Ϯ SD. Note the logarithmic scale on the y-axis. Coimmunoprecipitation. Two hundred microliters of protein G-Sepharose 4B beads (Sigma-Aldrich) per sample of ␣ plus ␤1 or ␣ plus ␤1B cell lines were rinsed three times with 1ϫ PBS and split into two microcentrifuge tubes. Beads were resuspended in 250 l of dilution buffer (60 mM Tris-HCl, pH 7.5, 180 mM NaCl, 1.25% Triton X-100, 6 mM EDTA, pH 8, with Complete Mini Protease Inhibitor Tablets) and incubated overnight with end-overend mixing at 4°C with 4 g of mouse or rabbit pan-VGSC antibody or 4 g of mouse or rabbit IgG, as indicated in the figure legends. Cells coexpressing ␣-plus ␤-subunits were resuspended in a 50 mM Tris, 10 mM EGTA, pH 8 solution (with Complete Mini) by scraping. The amount of sample used for each cell line was as follows: for HEKhNa v 1.1 cells transiently transfected or HEKhNa v 1.5 cells stably transfected with ␤1 or ␤1B, one 60 mm cell culture dish; for CHOhNa v 1.3 cells stably transfected with ␤1 or ␤1B, two 100 mm cell culture dishes. Cell suspensions were then centrifuged at 3000 ϫ g for 10 min at 4°C. Cells were washed again in Tris/EGTA solution, resuspended in 1 ml of dilution buffer, and incubated 30 min on ice for lysis. After a centrifugation step to remove insoluble material, one-half of the supernatant was added to the beads incubated with anti-pan-VGSC antibody and the other one-half to the beads incubated with IgG. Beads with cell lysates were incubated with end-over-end mixing for 4 h at 4°C, and then washed three times with washing buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 0.02% SDS, 5 mM EDTA, pH 8, with Complete Mini) and once with washing buffer without Triton X-100. Thirty-five microliters of Western blot sample buffer were then added to the beads, triturated, and incubated at 100°C for 5 min. Samples were then separated by SDS-PAGE on 10 or 18% polyacrylamide gels and transferred to nitrocellulose membranes for Western blot analysis.
Purification of ␤1B from conditioned media. Cells stably expressing V5-His epitope-tagged subunits were grown in one 850 cm 2 polystyrene roller bottle (Corning) containing 50 ml of media, or in 12 150 ϫ 25 mm cell culture dishes (Corning) containing 20 ml of media per dish until confluent (8 -15 d). The medium was not changed during this period but was supplemented with 1-2 ml of HI-FBS every 3-4 d. When cells reached confluence, conditioned media were collected and centrifuged to pellet cells that may have detached. The media were concentrated using a Millipore stirred cell concentrator, with a regenerated cellulose ultrafil- B, The C-terminal region of ␤1 is conserved between species. Alignments of the predicted amino acid sequences of the C-terminal region of ␤1 encoded by exons 4 and 5 in human, rat, and mouse using the CLUSTALW algorithm. Numbers above all alignments correspond to the human sequence. C, Hydrophobicity plots analyzing the amino acid sequences of rat ␤1 (left panel) or mouse ␤1 (right panel) show predicted hydrophobic signal peptide and transmembrane domains. D, The unique C-terminal region of ␤1B is not conserved between species. Alignments of the predicted amino acid sequences of the unique C-terminal region of ␤1B encoded by retained intron 3 in human, rat, and mouse using the CLUSTALW algorithm. Numbers above all alignments correspond to the human sequence. E, Hydrophobicity plots analyzing the amino acid sequences of rat ␤1B (left panel) or mouse ␤1B (right panel) show hydrophobic signal peptides but no transmembrane domains.
tration membrane (nominal molecular weight limit, 10,000) (Millipore) to obtain a volume of ϳ50 ml. Complete EDTA-free Protease Inhibitor Cocktail (Roche) was added to prevent degradation. Concentrated conditioned media were mixed with 1.2 ml total volume of His-Select HF Nickel Affinity Gel (Sigma-Aldrich), previously rinsed with deionized water and equilibration/washing buffer (50 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 10 mM imidazole) in a Poly-Prep Chromatography Column (Bio-Rad), and incubated for 30 min at RT on a Clay Adams Nutator Mixer (BD Biosciences). The mix was then centrifuged at maximum speed in a swinging bucket rotor for 5 min. The supernatant was discarded, and the nickel gel was resuspended in 15 ml of equilibration/ washing buffer. This washing step was repeated until the supernatant after centrifugation was completely clear. The nickel gel was resuspended in equilibration/washing buffer and transferred to the chromatography column in which the gel had been prerinsed. The nickel gel was then washed with 10 ml of equilibration/washing buffer, followed by elution buffer (50 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 250 mM imidazole), and the eluted fraction was collected in a Millipore Ultra-4 Centrifugal Filter Device with a 10,000 molecular weight cutoff regenerated cellulose filter (Millipore). The filter device was centrifuged at top speed in a swinging bucket rotor for 25 min, and the nonfiltered fraction was collected in a microcentrifuge tube where it was mixed with loading buffer containing SDS and ␤-mercaptoethanol at a 1:1 ratio. Western blot analysis was then performed. All results presented are representative of at least three repeats. Cerebellar granule neuron neurite outgrowth assays. Neurite outgrowth assays from P14 mouse cerebellar granule neurons (CGNs) were described previously (Davis et al., 2004) . Neurite length measurements were obtained from a minimum of 50 cells per condition from at least three independent experiments. Data from individual experiments were combined to provide an overall mean and SEM.
[
binding was performed on intact cells, analyzed, and normalized to total cellular protein as previously described .
Deglycosylation. Five microliters of whole-cell lysate from 1610-␤1BV5 were treated with PGNase F (New England Biolabs; P0704S) following the instructions of the manufacturer. After enzymatic deglycosylation, the sample was mixed with Western blot sample buffer, separated by SDS-PAGE on a 10% polyacrylamide gel, and transferred to nitrocellulose for Western blot analysis. Another 5 l aliquot of untreated wholecell lysate was included on the Western blot as a negative control.
Whole-cell patch-clamp recording and analysis. Micropipettes were obtained from capillary glass tubing (Warner Instruments) using a horizontal P-97 puller (Sutter Instrument). Micropipettes resistance was between 1.5 and 3.5 M⍀, when filled with intracellular solution containing the following (in mM): 10 NaCl, 20 CsF, 95 CsCl, 10 EGTA, and 10 HEPES, pH 7.4 with CsOH; and the extracellular solution containing the following (in mM): 60 NaCl, 4 KCl, 1.5 CaCl 2 , 1 MgCl 2 , 5 glucose, 10 HEPES, 70 CsCl, pH 7.4 with NaOH. Voltage pulses were applied, and data were recorded using Clampex 9.2, Axopatch 200B amplifier, and a Digidata 1322A digitizer (Molecular Devices). Pipette and whole-cell capacitance were fully compensated. When appropriate, series resistance compensation was set to ϳ40 -70% with the lag set to 10 s. Signals were low-pass filtered at 5 kHz, and data were sampled at 40 kHz on-line. To determine the Na ϩ current amplitude and voltage dependence of activation, Na ϩ currents were evoked by depolarization to different 250 ms test pulses (from Ϫ110 to Ϫ70 mV at 10 mV intervals, from Ϫ70 to Ϫ10 mV at 5 mV intervals, and from Ϫ10 to 40 mV at 10 mV intervals) from a holding potential of Ϫ80 mV and a hyperpolarizing Ϫ120 mV, 500 ms prepulse. Peak Na ϩ current was normalized to cell capacitance and used to plot I-V curves and calculate conductance [g ϭ I/(V Ϫ V rev ), where V is the test potential, and V rev is the measured reversal potential]. Voltage dependence of inactivation was determined by applying a 50 ms test pulse of 0 mV after 250 ms prepulses to the same voltages as described for the voltage dependence of activation. Peak currents were normalized to the maximum peak I Na amplitude. Normalized activation and inactivation curves were fit with a Boltzmann equation
where V 1/2 is the membrane potential in the midpoint of the curve, and is the slope factor. To assess the time course of recovery from inactivation, a prepulse to 0 mV for 20 ms was followed by a recovery interpulse of variable duration (from 0.25 to 750 ms) to Ϫ120 mV and then a 25 ms test pulse to 0 mV to determine the fraction of recovered channels. Peak Na ϩ currents during the test pulse were normalized to the peak Na ϩ current during the corresponding prepulse and plotted as fractional recovery (F r ) against time. Data were then fit with one exponential to determine the time constants for recovery, using the equation
, where is the constant of recovery. The kinetics of inactivation was measured on the test pulse to 0 mV from the same protocol used for voltage dependence of activation. The current, from 90% of the peak amplitude to 20 ms after the test pulse was initiated, was fitted to a double-exponential equation of the form I ϭ (F f *exp(Ϫt/ f )) ϩ (F s *exp(Ϫt/ s ) ϩ C, using the Chebyshev method, where I is the current, f and s are the time constants for the fast and slow inactivation component, and C is the steady-state persistent current. Analysis of the recorded Na ϩ current was performed using the software packages Clampfit 9.0.2 (Molecular Devices) and SigmaPlot 11.2 (Systat Software).
Clinical samples. A group of 360 unrelated probands [122 males (m) and 238 females (f)] diagnosed with epilepsy (n ϭ 118; 42 m, 76 f), migraine (n ϭ 110; 23 m, 87 f), Tourette's syndrome (n ϭ 35; 23 m, 12 f), essential tremor (n ϭ 25; 7 m, 18 f), bipolar disorder (n ϭ 66; 24 m, 42 f), episodic ataxia (n ϭ 4; 3 m, 1 f), episodic vertigo (n ϭ 1 f), or episodic fainting (n ϭ 1 f) were studied. Subjects were ascertained on the basis of family studies and routine clinical practice. Diagnoses were performed by clinicians specialized in these neurological disorders. For most patients, additional clinical information allowed for a better definition of the disease subphenotype, especially in cases of epilepsy, bipolar disorder, and migraine. The ethnic origin of all subjects is known, and additional affected and nonaffected family members for each proband Western blot showing surface biotinylation of 1610 cells stably transfected with V5-His-tagged ␤1B (␤1B) or V5-His-tagged ␤1 (␤1) (top panel). Robust ␤1B expression was observed in the whole-cell lysate (Lysate S1). This same cell clone (S1) was assayed by surface biotinylation (Biotin S1), showing the absence of ␤1B at the cell surface. An independent ␤1B-V5 clone (S2) gave a similar result. A biotinylated sample from 1610 cells stably transfected with V5-Histagged ␤1 (Biotin ␤1) was used as positive control for cell surface expression. A Western blot of the same samples with anti-Na ϩ /K ϩ ATPase ␤1 showed equal loading of surface proteins (bottom panel). B, ␤1B but not ␤1 is expressed in conditioned media. Top panel, Conditioned media from 1610 cells stably expressing ␤1V5 (Cond. Media ␤1) or ␤1BV5 (Cond. Media ␤1B) were analyzed by Western blot and probed with anti-V5. A surface biotinylated sample of 1610-␤1V5 cells (Biotin ␤1) is a positive control. Bottom panel, Ponceau red staining of the membrane demonstrates protein in all lanes. C, ␤1B is a glycoprotein. Western blot of 1610-␤1BV5 whole-cell lysates before (left lane) and after (right lane) treatment with PNGase F. The bottom immunoreactive band is consistent with the molecular weight of fully deglycosylated ␤1B (ϳ26 kDa). All blots are representative of three experimental repeats. Molecular weight markers are given in kilodaltons. The arrows indicate ␤1-or ␤1B-immunoreactive bands. studied were collected for cosegregation/pedigree analysis. Informed consent was obtained from all participants, and study protocols were approved by the ethics committees of the institutions where collections occurred. An additional cohort of 192 unrelated Tourette's patient samples (150 m, 42 f) was used to assess involvement of the p.G257R variant in Tourette's syndrome.
Amplicon design and PCR for patient samples. Amplicons were designed to minimize the amount of intronic sequence and to avoid repetitive elements. PCR primers were designed using PrimerSelect (DNASTAR) and purchased from BioCorp. Primer sequences, amplicon sizes, and amplification conditions are given in Tables 1 and 2 . Genomic DNA was isolated from blood samples using conventional methods. Samples were amplified using TaqDNA polymerase (QIAGEN) on a PE 9700 PCR thermocycler (PerkinElmer). Amplification conditions were determined by testing several annealing temperatures, and by addition of Q solution (QIAGEN) for problematic amplicons on control genomic DNA samples. All amplified fragments were tested by agarose gel electrophoresis.
Denaturing HPLC and sequence analysis. PCR fragments were optimized for melting temperature on a model 3500HT WAVE denaturing HPLC (dHPLC) (Transgenomic) with Wavemaker software, version 4.1.44. After PCR and dHPLC optimization, PCR fragments from DNA samples were amplified using the optimized conditions and the fragments were then tested on agarose gels. Amplified fragments were pooled four times, denatured at 95°C in a heating block for 5 min, and renatured slowly by cooling the block to 25°C over the course of 1 h. The pooled PCR fragments were run on the dHPLC apparatus at two different melting temperatures. The elution profiles of each sample pool were compared, and samples from one to three pools showing variant elution profiles were selected for sequence determination at the Genome Quebec Innovation Centre Sequencing Facility (Montréal, Québec, Canada). Sequencing reactions were performed on an ABI Prism 3700 sequencing apparatus using manufacturer's recommended conditions. Sequence traces were aligned using SeqManII (DNASTAR). Base pair variants were identified and annotated. Publicly available predicted single-nucleotide polymorphisms (SNPs) (from NCBI dbSNP, version 132) were identified, and those found in the sequence alignment were noted.
Genotyping of patient samples. Genotyping was performed by direct sequencing, allele-specific oligonucleotide (ASO) hybridization, or restriction fragment length polymorphism (RFLP) assay. Genotypes were scored manually or generated using Mutation Surveyor (SoftGenetics). For each ASO assay, two oligonucleotides were designed to differentiate wild-type from the mutant alleles. The ASO assays were done as described previously (Bourgeois and Labuda, 2004) . Briefly, each oligonucleotide was end-labeled with [␥- 32 P]dATP using T4 kinase in a 25 l of total reaction volume. Probes were hybridized to nylon membranes to which was affixed the desired PCR amplified fragments, washed, and exposed to x-ray film. Films were scored and the genotypes for all successfully amplified samples were determined. The p.G257R variant was genotyped using an MspI RFLP assay. The 465 bp fragment from amplicon 3B (Table 1) was digested with MspI restriction enzyme (New England Biolabs), and the products were separated on a 1.5% agarose gel. The 257Gly allele yields digested products of 49, 87, 90, and 239 bp in size, whereas the 257Arg allele yields fragments of 49, 87, and 329 bp in size.
Statistical analyses. Continuous data, n Ͻ 200, were tested for normality using the Kolmogorov-Smirnov test. All continuous data were tested for homogeneity of variances using the Levene test. These data were normally distributed, and thus group means were compared using twotailed Student's t test or ANOVA. If homogeneity of variance existed, Tukey's test was selected as the post hoc test; otherwise, Tamhane's T2 was used. Statistical significance was set at p Ͻ 0.05. SPSS was used for all determinations of statistical significance. The bar graphs were obtained using SPSS, Origin 7 (OriginLab Corporation), or Prism 5 (GraphPad).
Results

Expression patterns of ␤1 and ␤1B in human brain are developmentally regulated
We demonstrated previously that ␤1 and ␤1B mRNA have complementary expression patterns in rat brain (Kazen-Gillespie et al., 2000). ␤1B is expressed predominantly during embryonic rat brain development, with levels decreasing after birth. In contrast, ␤1 expression is low in embryonic rat brain, but becomes dominant over ␤1B in postnatal brain. To determine whether this developmental expression pattern is conserved in humans, we performed RT-PCR using primers specific for ␤1 or ␤1B and human frontal lobe total RNA as template. Samples were obtained from both human embryonic brain (22 and 36 weeks of gestation) and human postnatal brain (age range, 9 -56 years). In addition, we obtained occipital lobe total RNA from the postnatal subjects. RNA from Scn1b-null mouse brain was used as a negative control. At the earliest time point assayed, 22 weeks of gestation, both variants were detected, although higher levels of ␤1B were detected compared with ␤1. As development progressed, the level of ␤1B appeared to remain relatively constant while the level of ␤1 increased (Fig. 1 A) . To quantify these results, we prepared cDNA from each RNA sample and performed quantitative PCR using the TaqMan assay. Ratios of ␤1 to ␤1B were compared using the 2 Ϫ⌬CT method. At 22 weeks of gestation, ␤1:␤1B ϭ 0.08 (mean 2 Ϫ⌬CT Ϯ SD, 0.08 Ϯ 0.15). At 36 weeks of gestation, ␤1B and ␤1 levels were similar (␤1:␤1B, 1.22 Ϯ 0.91). After birth, levels of ␤1 transcript were ϳ18-fold higher than ␤1B (␤1:␤1B, 17.84 Ϯ 3.45; Fig. 1 B) . We found no significant differences between results obtained from the various postnatal subjects (data not shown), and thus these values were pooled.
VGSC ␤1B is a secreted protein
The topology of ␤1 is well understood (Isom et al., 1992) ; however, less is known about ␤1B. In silico analyses of the predicted amino acid sequences of human ␤1 and ␤1B were performed using the Goldman Engelman Steitz hydrophobicity scale as described in Materials and Methods. In contrast to ␤1 (Isom et al., 1992) , a hydrophobic transmembrane domain was not predicted for ␤1B (Fig. 2 A) . The predicted ␤1 and ␤1B amino acid sequences from rat and mouse were analyzed similarly for hydrophobicity. In contrast to predicted amino acid sequences for ␤1 from these species, which are highly conserved and contain predicted hydrophobic domains (Fig. 2 B, C) , very little similarity Figure 5 . ␤1B is detected in the ER in the absence of Na v 1.5, and at the cell surface when coexpressed with Na v 1.5. Cells expressing ␤1V5, ␤1BV5, ␤1Fc, or ␤1BV5 plus Nav1.5 were labeled with anti-PDI to mark the ER, and anti-V5 or anti-Fc antibodies to label ␤-subunits. Merged images are presented with and without bright-field (BF) illumination to clearly show both fluorescent signal as well as identify cell borders. A-D, 1610-␤1BV5 cells display strong anti-V5 signal coincident with anti-PDI signal (D, arrow). E-H, 1610-␤1V5 cells display a diffuse anti-V5 signal but lack the ER localization seen in 1610-␤1B cells, consistent with plasma membrane expression of ␤1 (F, H, arrows) . I-L, CHO-␤1Fc cells display strong overlap of anti-Fc and anti-PDI immunofluorescence, consistent with the nature of ␤1Fc as a secreted protein. M-P, HEK-␤1BV5-Nav1.5 cells display diffuse anti-V5 signal that extends beyond the ER, including expression within filipodial structures at the cell border (N, arrows). Scale bar, 20 m.
was found in the C-terminal region unique to ␤1B, suggesting that the sequence of this domain is species specific (Fig. 2 D) . Importantly, none of these unique ␤1B sequences contained a predicted transmembrane domain, suggesting that ␤1B may be a secreted protein (Fig. 2 E) .
To investigate whether ␤1B is indeed a secreted protein, we stably transfected Chinese hamster lung 1610 fibroblasts with a V5-His epitope-tagged human ␤1B cDNA construct (1610-␤1BV5). Protein expression at the cell surface was assessed by surface biotinylation, probing the final Western blot with anti-V5 antibody. 1610 cells stably expressing ␤1V5 (1610-␤1V5) were used as a positive control (Patino et al., 2009) , and as expected, ␤1V5 was detected at the cell surface (Fig. 3A) . In contrast, ␤1BV5 was not detected at the cell surface despite abundant levels of ␤1BV5 protein in the whole-cell lysate sample (Fig. 3A) . We next assayed conditioned media by Western blot to test for the presence of ␤1B. Anti-V5-immunoreactive bands were present in conditioned media from 1610-␤1BV5 cells, while, as expected, no bands were detected in media from 1610-␤1V5 cells despite high levels of protein present on the Ponceau redstained blot (Fig. 3B) .
The migration of ␤1B by SDS-PAGE was variable, over a size range of ϳ26 kDa (the predicted molecular weight of nonglycosylated ␤1B) to 45 kDa, with the majority of experimental results showing the ϳ45 kDa band. Interestingly, the same clonal line of 1610-␤1BV5 cells yielded bands of different sizes in different experiments. We hypothesized that these bands might represent different glycosylation states of ␤1B and that enzymes present in the culture medium or experimental solutions might result in artifactual deglycosylation of this protein. To test this, whole-cell lysates of 1610-␤1BV5 cells were treated with PNGase F and samples were then analyzed by Western blot. PNGase F treatment resulted in collapse of the ␤1B-immunoreactive band from ϳ45 to ϳ26 kDa (Fig. 3C) , suggesting that the various immunoreactive ␤1B bands identified in the conditioned media represent different glycosylation states. Together, these data suggest that both ␤1 and ␤1B are glycoproteins. Furthermore, they suggest that, while ␤1 has transmembrane topology, ␤1B is a secreted protein that may be critical during embryonic brain development.
Differential effects of VGSC ␣-subunits on ␤1B cell surface expression
The experiments in Figure 3 demonstrate that ␤1B is secreted from cells that do not express VGSCs. To test whether the presence of a VGSC ␣-subunit may result in retention of ␤1B at the cell surface, we studied cell lines coexpressing human ␤1BV5 with human VGSC ␣-subunits. Because SCN1B mutations affecting the region specific to ␤1B are associated with cardiac arrhythmia (Watanabe et al., 2008) and epilepsy (shown here), we tested the effects of human Na v 1.1, a common target of genetically determined epilepsy (Meisler et al., 2010) , and human Na v 1.5, the VGSC ␣-subunit most prevalent in heart and a target of inherited arrhythmia (Catterall et al., 2005; Remme et al., 2008; Ruan et al., 2009 ). In addition, because ␤1B is mainly expressed during embryonic brain development (Fig. 1) , we tested the effects of human Na v 1.3, the predominant VGSC expressed in embryonic brain (Catterall et al., 2005) . For unknown reasons, we were unable to establish stable ␤1V5-or ␤1BV5-expressing cell lines using HEKhNa v 1.1 cells (Patino et al., 2009 ). Thus, all experiments with this cell line were performed following transient transfection of ␤1V5 or ␤1BV5 cDNA. We were able to establish stable ␤-subunit-expressing lines using HEK cells stably transfected with human Na v 1.5 (HEKhNa v 1.5). Finally, Chinese hamster ovary fibroblasts stably expressing human Na v 1.3 (CHOhNa v 1.3) (Meadows et al., 2002a) were stably transfected with human ␤1 or ␤1B cDNAs. Similar to 1610 cells expressing no VGSC ␣-subunits, ␤1B was not detected at the surface of cells coexpressing Na v 1.1 or Na v 1.3 (Fig. 4 A) , suggesting that ␤1B is secreted despite the presence of these channels. In contrast, cell surface ␤1B expression was detected in biotinylated samples from cells coexpressing Na v 1.5 and ␤1B (Fig. 4 A) , suggesting that ␤1B may be selectively retained at the cell surface by this channel and consistent with previous results showing modulation of Na v 1.5-mediated Na ϩ current by ␤1B (Watanabe et al., 2008) .
Effects of ␤1 and ␤1B on VGSC ␣-subunit cell surface expression ␤1 associates with multiple VGSC ␣-subunits and increases their functional expression. For example, ␤1 associates with Na v 1.2 and this association is functionally detected by increased Na Table 3. current density and by increased cell surface [ 3 H]STX binding (Isom et al., 1995; . Rat ␤1B increases the cell surface expression of rat Na v 1.2 in transfected cells, with subtle changes in current activation and inactivation, suggesting that these subunits functionally associate . Similarly, human ␤1B coexpression increases Na ϩ current density generated by human Na v 1.5 (Watanabe et al., 2008) , again suggesting functional association. In the following set of experiments, we asked whether specific ␣-and ␤1-or ␤1B-subunits associate and whether coexpression of ␤1 or ␤1B results in increased ␣-subunit cell surface expression.
We used coimmunoprecipitation assays to examine whether human ␤1B associates with human Na v 1.1, human Na v 1.3, or human Na v 1.5. In these experiments, anti-pan-VGSC antibody was used for the immunoprecipitation step from Triton X-100-solubilized whole-cell lysates, and Western blots were probed with anti-V5 to detect associated ␤-subunits. ␤1 coprecipitated with Na v 1.1 (Fig. 4 B) , Na v 1.3 (Fig. 4C) , and Na v 1.5 (Fig. 4 D) . In contrast, ␤1B association was not detected with any ␣-subunit (Fig. 4 B-D) . Western blots of whole-cell lysates from each cell line coexpressing ␣-and ␤1BV5-subunits demonstrated the presence of ␤1B in all three (Fig. 4 E) . Lack of association between Na v 1.5 and ␤1B in the coimmunoprecipitation assay contrasts with our result above, showing cell surface retention of ␤1B in the presence of Na v 1.5, and with those of others (Watanabe et al., 2009) . Possible explanations for this discrepancy may be that the interaction between ␤1B and Na v 1.5 is disrupted by detergent solubilization or that Na v 1.5 and ␤1B associate transiently or with low affinity such that their interaction cannot be captured biochemically.
We performed immunofluorescent labeling of cells transfected with ␤1BV5, ␤1V5, ␤1Fc, or ␤1BV5 plus Na v 1.5 to assess the subcellular localization of each of these ␤-subunits (Fig. 5) . Anti-V5 staining of ␤1BV5 cells demonstrates ␤1B ER localization, as indicated by anti-V5 immune signal coincident with that for the ER marker PDI (Fig. 5A-D) . In contrast, ␤1V5, which has been shown previously to be a transmembrane protein (Isom et al., 1992) , is more evenly distributed in all cell areas, including the cell surface (Fig. 5E-H ) . As a control for the subcellular distribution of a known secreted protein, we performed a similar labeling experiment using ␤1Fc, which we have shown previously to be a secreted protein (Fig. 5I-L) . This engineered, secreted form of ␤1 displays strong overlapping fluorescent signals with that of PDI, similar to the overlap observed in ␤1BV5 cells. Finally, we stained cells coexpressing ␤1BV5 plus Na v 1.5 subunits with anti-V5 and anti-PDI to visualize ␤1B in the presence of a VGSC ␣-subunit ( Fig. 5M-P) . In addition to its localization in intracellular organelles, and consistent with surface biotinylation assays (Fig. 4 A) , ␤1BV5 staining was detectable at the cell surface (Fig. 5N, arrows) , particularly in filopodia-like extensions at the cell borders. Together, these immunofluorescence results suggest that ␤1B is a secreted protein. Furthermore, they confirm that the subcellular distribution of ␤1B is altered when coexpressed with Na v 1.5.
[ 3 H]STX binding to intact cells was used to assay Na v 1.3 cell surface expression in the presence and absence of ␤-subunits. Because STX is membrane impermeant, binding to intact cells measures only cell surface and not intracellular channels (McEwen et al., , 2009 pared with cells expressing only Na v 1.3 (Na v 1.3 plus ␤1B, 5.90 Ϯ 0.92 fmol/mg).
Functional modulation of Na ؉ current by ␤1B
We showed previously that rat ␤1B exerted subtle but significant effects on rat Na v 1.2-generated Na ϩ current activation and inactivation in transfected cells . To examine whether coexpression of ␤1 or ␤1B modulated Na v 1.3-generated Na ϩ current, we performed whole-cell patch-clamp recordings on CHO hNa v 1.3 cells in the presence and absence of stable expression of human ␤1 or ␤1B. Consistent with our coimmunoprecipitation and [ 3 H]STX binding results, ␤1 coexpression had significant effects on Na ϩ current. ␤1 significantly increased Na ϩ current density at test potentials over a range from Ϫ45 to 0 mV ( Fig. 6A ) and shifted the voltage dependence of activation by ϳ6 mV and the voltage dependence of inactivation by ϳ12 mV, both in the hyperpolarizing direction. In contrast, ␤1B produced more subtle changes. ␤1B coexpression resulted in a minor increase in Na ϩ current density and a small hyperpolarizing shift in the voltage dependence of current activation; however, these changes were not statistically significant (Fig. 6 A, B) . ␤1B had no measurable effect on the voltage dependence of current inactivation (Fig. 6C) . Both ␤1 and ␤1B modulated the kinetics of inactivation and recovery from inactivation ( Fig. 6 D, Table 3 ). ␤1 and ␤1B decreased the time constant, , of fast inactivation, although ␤1 had a more significant effect than ␤1B (Table 3) . Interestingly, ␤1 and ␤1B had opposite effects on the kinetics of recovery from inactivation: ␤1 coexpression increased, while ␤1B expression decreased, compared with ␣ alone. In summary, coexpression of Na v 1.3 plus ␤1 resulted in increased Na ϩ current density, decreased channel availability, acceleration of the development of fast inactivation, and deceleration of the rate of recovery from inactivation compared with Na v 1.3 alone. In contrast, coexpression of Na v 1.3 plus ␤1B accelerated the development of fast inactivation and increased the rate of recovery from inactivation compared with Na v 1.3 alone. These results suggest that, even though secreted, ␤1B may exert subtle effects on Na ϩ current in brain neurons. Furthermore, these effects may be autocrine or paracrine.
␤1B stimulates neurite outgrowth in CGNs through ␤1 adhesion VGSC ␤-subunits contain a single extracellular Ig domain and function as CAMs (Malhotra et al., 2000 (Malhotra et al., , 2002 . ␤1 promotes CGN neurite outgrowth in vitro and in vivo through trans homophilic cell-adhesive interactions (Davis et al., 2004; Brackenbury et al., 2008a Brackenbury et al., , 2010 . Because ␤1 and ␤1B contain identical Ig loop domains, we hypothesized that ␤1B may function as a secreted CAM to promote neurite outgrowth. Previous results using an engineered soluble ␤1 extracellular domain to promote CGN neurite outgrowth and to bind to other CAMs support this idea (Davis et al., 2004; . To test this hypothesis, we investigated the ability of ␤1B to promote neurite outgrowth of CGNs. CGNs were isolated from P14 C57BL/6 mice and plated on monolayers of untransfected 1610 cells (as a negative control), 1610-␤1V5 cells (as a positive control), or 1610-␤1BV5 cells, as described in Materials and Methods. After 24 h of incubation, cells were fixed and immunostained with anti-GAP43, and the length of the longest neurite was measured. Consistent with previous results (Davis et al., 2004; Brackenbury et al., 2008a) , the mean neurite length of CGNs plated on 1610-␤1V5 cells (mean Ϯ SE, 64.88 Ϯ 2.63 m) was significantly greater than CGNs plated on 1610 cells (40.64 Ϯ 1.70 m). Importantly, the mean neurite length of CGNs plated on 1610-␤1BV5 cells (69.43 Ϯ 2.46 m) was also statistically greater than CGNs plated on 1610 cells, and not significantly different from cells plated on 1610-␤1V5 cells (n ϭ 300 for each group; p Ͻ 0.001; Fig. 7A ). Examples of CGN neurite length are shown in Figure 7B . Thus, similar to ␤1, ␤1B functions as a CAM to promote neurite outgrowth. In contrast to ␤1, however, we propose that ␤1B functions as a secreted rather than as a transmembrane CAM.
The neurite outgrowth-promoting activity of ␤1 is abolished in CGNs isolated from Scn1b-null mice (Davis et al., 2004) , demonstrating that trans homophilic ␤1-␤1 interactions are required. To test whether a similar requirement of ␤1 expression on the neuron exists for ␤1B signaling, we compared neurite outgrowth of CGNs isolated from Scn1b-null mice versus wild-type controls plated on ␤1B-secreting monolayers. In agreement with our previous studies (Davis et al., 2004) , the mean neurite length of wild-type CGNs plated on 1610-␤1V5 cells (75.46 Ϯ 2.44 m) was statistically greater than for Scn1b-null CGNs (36.42 Ϯ 1.45 m). Similarly, the mean neurite length of wild-type CGNs plated on 1610-␤1BV5 cells (75.06 Ϯ 2.71 m) was significantly higher than that of null CGNs (38.66 Ϯ 1.69 m; n ϭ 300 per condition; p Ͻ 0.001; Fig. 7C ). There was no significant differ- Figure 8 . A SCN1B mutation that affects ␤1B is found in two pedigrees of idiopathic epilepsy. A, Genomic structure of SCN1B. Exons 1-6 constitute ␤1. Extension of exon 3 into intron 3 generates the variant, ␤1B. The novel 3Ј end of ␤1B does not contain a transmembrane domain (TM). The asterisk (*) indicates the position of the G257R mutation. (This is not drawn to scale.) B, Chromatogram showing the p.G257R heterozygous missense mutation in the epilepsy proband from pedigree 1 (bottom row), whereas it is absent from a control individual (top row). C, Two pedigrees segregating the p.G257R missense mutation. Pedigree 1 has epilepsy, whereas pedigree 2 has epilepsy and Tourette's syndrome. Affected individuals are indicated with black symbols, and normal individuals are shown with white symbols. 1, 257Gly allele; 2, 257Arg allele. NA, Not available.
ence between the mean neurite lengths of wild-type or null CGNs plated on 1610-␤1V5 cells versus those on 1610-␤1BV5 cells. These data demonstrate that the neurite outgrowth-promoting ability of ␤1B requires interaction with ␤1-subunits present at the neuronal surface, similar to the mechanism described for ␤1 (Brackenbury et al., 2008a (Brackenbury et al., , 2010 .
A SCN1B mutation affecting ␤1B may be a risk factor for idiopathic epilepsy Mutations in SCN1B are associated with human disease, including epilepsy and cardiac arrhythmia Watanabe et al., 2008 Watanabe et al., , 2009 Patino et al., 2009) . While one mutation specific to the region encoding ␤1B is linked to Brugada syndrome (Watanabe et al., 2008) , to date all of the SCN1B epilepsy mutations occur in the Ig domain shared by ␤1 and ␤1B (Patino and Isom, 2010) . To test the hypothesis that SCN1B mutations specifically affecting ␤1B and not ␤1 may be associated with epilepsy as well as arrhythmia, all SCN1B exons and intron 3, which is retained in ␤1B (Fig. 8 A) Qin et al., 2003) , were amplified by PCR as part of a screening study of 150 genes in 360 unrelated patients with episodic brain disorders (118 with epilepsy, 110 with migraine, 66 with bipolar disorder, 35 with Tourette's syndrome, 25 with essential tremor, 4 with episodic ataxia, 1 with episodic vertigo, and 1 with episodic syncope). A total of 14 SCN1B variants were identified, of which 5 resulted in amino acid substitutions in the unique region encoding ␤1B (Table 4) . Of these, three had minor allele frequencies (MAFs) Ͼ 0.1 (p.L210P, p.S248R, and p.R250T) and occurred in all cohorts of patients. A variant (p.R214Q) had MAF ϭ 0.005 but was also present in four of eight cohorts. One variant (p.G257R) was identified in two unrelated probands with idiopathic epilepsy (MAF ϭ 0.002) as a heterozygous mutation (Fig. 8 B) . One of those probands belonged originally to the Tourette's cohort, but upon further clinical investigation this patient was found to be comorbid for epileptic seizures, suggesting that this variant was associated with an epilepsy phenotype. The patient from pedigree 1 had tonic-clonic seizures starting from 10 years of age. The proband's mother and maternal aunt also had a history of seizures. The patient from pedigree 2 had right temporal seizures with secondary generalized seizures starting at 15 years of age, sometimes preceded by an aura. Seizures were controlled by Tegretol. This patient was also diagnosed with Gilles de la Tourette syndrome, with facial tics and aggressive impulsions. There was no family history of epilepsy in either parent.
To further examine whether the p.G257R variant was associated with Tourette's syndrome, an additional 192 unrelated Tourette's probands were genotyped (data not shown). The variant was not detected in this additional cohort, suggesting that p.G257R is not associated with increased risk of Tourette's syndrome. We screened an additional 187 normal control samples for the portion of intron 3 encoding the unique region of the ␤1B splice variant. One normal individual was identified with the p.G257R variant, perhaps suggesting incomplete penetrance similar to other SCN1B mutations Watanabe et al., 2008) .
To examine the segregation of p.G257R, additional samples from the probands' available family members were genotyped. For pedigree 1, both the proband and her mother carried the mutation and suffered from epilepsy. For pedigree 2, the mutation was inherited from the mother, but there was no reported history of seizures in either parent (Fig. 8C) .
␤1B p.G257R is a trafficking-deficient mutation resulting in a functional null allele To investigate the mechanism by which ␤1B p.G257R might contribute to seizures, we stably transfected 1610 cells with V5-Histagged p.G257R cDNA (1610-p.G257RV5). In contrast to wild-type ␤1BV5, p.G257RV5 was not detected in conditioned media (Fig.  9A ) despite high levels of expression of the protein in the wholecell lysates (Fig. 9B ) and overall protein expression in the Ponceau red-stained blot (Fig. 9A, bottom panel) . We used surface biotinylation assays to determine whether p.G257RV5 might be present at the cell surface. As demonstrated in Figure 9B , p.G257RV5 was detected in the whole-cell lysate but not in the conditioned media or on the cell surface. From these data, we concluded that p.G257R is a trafficking-deficient mutant. To confirm that the trafficking deficiency of p.G257R is specifically pathogenic, we tested three other SCN1B non-seizure-related polymorphic variants containing amino acid substitutions in ␤1B found in our cohort of patients: p.R214Q, p.S248R, p.R250T. These variants were present in each disease cohort and hence were not associated with epilepsy (Table 4) . To facilitate detection of these proteins, V5-His epitope tags were inserted at their C termini, similar to p.G257RV5. 1610 cells were stably transfected and conditioned media were collected. In contrast to p.G257RV5, all three variants were detected in the conditioned media similar to wild-type ␤1BV5 (Fig. 9C) . These results suggest that the lack of secretion of p.G257R is a pathogenic change and not a normal variability present in ␤1B polymorphisms. Consistent with the observed intracellular retention of p.G257RV5, wild-type CGNs plated on 1610-p.G257RV5 cell monolayers had mean neurite lengths that were indistinguishable from those plated on untransfected 1610 cells (1610 ( -p.G257RV5, 40.87 Ϯ 1.56 m, vs 1610 .96 Ϯ 1.63 m; n ϭ 300 and 200, respectively) and significantly shorter than CGNs plated on 1610-␤1V5 (70.02 Ϯ 2.07 m; n ϭ 300) or 1610-␤1BV5 (65.89 Ϯ 2.31 m; n ϭ 300; p Ͻ 0.001) (Fig. 9D ). These results demonstrate that p.G257R is a functional null allele.
To test whether p.G257R may inhibit ␤1 cell surface expression via a dominant-negative function, 1610-␤1V5 cells were stably transfected with cDNA encoding either ␤1B or p.G257R in pTRACER-CMV2. This plasmid encodes EGFP under control of a separate promoter than that used for the multiple cloning site. After stable transfection, Ͼ99% of the 1610-␤1V5 cells coexpressing ␤1B or p.G257R showed green fluorescence, confirming ␤1B or p.G257R protein expression (Fig. 10 A, C) . Surface bioti- 1610-␤1BV5cellswerestablytransfectedwiththepTRACER-CMV2construct,fixedwith4%parafor-maldehyde,andmonitoredforGFPfluorescence(leftpanels)andbright-fieldimages(rightpanels),as indicated, using confocal microscopy. UT indicates untransfected cells. Scale bars, 100 m. D, p.G257R does not inhibit secretion of ␤1B. Conditioned media from two independent cell clones coexpressing ␤1BV5 and p.G257R (p.G257R S1 and S2) were collected and analyzed by Western blot with anti-V5. Conditioned media from 1610-␤1BV5 cells (UT) was a positive control. nylation assays were subsequently performed on 1610-␤1V5 cells or 1610-␤1V5 cells coexpressing either wild-type ␤1B or p.G257R in pTRACER-CMV2. Surface expression of ␤1V5 was detected by probing the Western blots with anti-V5 antibody. All lanes showed similar levels of ␤1V5 surface expression, indicating that coexpression of ␤1B or p.G257R did not interfere with ␤1 trafficking to the plasma membrane (Fig. 10 B) . A similar strategy was used to assess whether p.G257R functioned as a dominant negative for wild-type ␤1B secretion. Stably transfected 1610-␤1BV5 cells were transfected with p.G257R in pTRACER-CMV2 (Fig. 10C) . Western blots of conditioned media were probed with anti-V5 to detect wild-type ␤1B secretion. Conditioned media collected from 1610-␤1BV5 cells were used as a positive control. Comparable levels of anti-V5-immunoreactive bands were detected in all lanes, demonstrating that p.G257R does not interfere with wild-type ␤1B secretion (Fig. 10 D) .
Are other SCN1B epilepsy-linked mutations trafficking deficient? SCN1B p.R125C (Patino et al., 2009) and p.G257R (above) are retained intracellularly. Is this a general mechanism of SCN1B-linked epilepsy? To test this possibility, we expressed SCN1B p.C121W (Wallace et al., 2002b) and p.R85H in 1610 cells and performed surface biotinylation assays as described for Figure 3 . As shown in Figure 11 , in contrast to p.R125C and p.G257R and in agreement with our previous study of p.C121W (Meadows et al., 2002b) , both of these mutants were observed to be robustly expressed at the cell surface. Thus, at least in heterologous cells, intracellular retention resulting in a functional null phenotype is not a general mechanism of SCN1B-linked epilepsy.
Discussion
Despite an extensive literature demonstrating dramatic effects of ␤1-subunit coexpression on Na ϩ current in heterologous systems, the major role of SCN1B in vivo appears to be cell adhesion (Patino and Isom, 2010) . Studies with Scn1b-null mice show that this gene plays significant roles in promoting neuronal migration, neurite extension, and axonal fasciculation in brain and corticospinal tract (Brackenbury et al., 2008a (Brackenbury et al., , 2010 . While many studies have shown dramatic Scn1b-mediated Na ϩ current modulation in heterologous systems in vitro (for review, see Patino and Isom, 2010) , the observed effects of Scn1b deletion or mutation on Na ϩ current in vivo are neuronal cell type specific and more subtle than observed in Xenopus oocytes or transfected cells Aman et al., 2009; Brackenbury et al., 2010; Uebachs et al., 2010; Wimmer et al., 2010) . It is important to consider, however, that multiplication of these small effects through synaptic networks may result in large changes in excitability in vivo. Na ϩ current is required for Scn1b-mediated neurite outgrowth (Brackenbury et al., 2010 ), but we argue that Scn1b-mediated modulation of Na ϩ current is not. Localization of Na v 1.6 to the axon initial segment is modulated by Scn1b and is critical for Scn1b-mediated neurite outgrowth in CGNs (Brackenbury et al., 2010) . However, this effect is likely attributed to Scn1b-mediated cell-adhesive interactions and not Scn1b-mediated Na ϩ current modulation. Clearly, Scn1b plays multifunctional signaling roles in vivo. A critical future experiment will be to separate the effects of Scn1b on Na ϩ current modulation from those on cell adhesion to assess their relative impacts in brain in vivo.
The present results emphasize that understanding the physiological role of SCN1B in brain must include consideration of the structure and function of ␤1B in addition to ␤1. This is underappreciated in the field, as most studies have considered only ␤1. Our results showing that ␤1B is a secreted CAM expressed in embryonic brain that exerts only subtle effects on neuronal VGSC ␣-subunits suggest that this splice variant may play critical roles in SCN1B function during brain development through nonconducting cell adhesive mechanisms. Interestingly, because ␤1B is a secreted protein, it may play autocrine or paracrine roles in neuronal pathfinding. Deletion of ␤1B may make a significant contribution to the severe neurological Scn1b-null phenotype. This phenotype includes not only Scn1b-null mice but also the functional null SCN1B p.R125C mutation linked to Dravet syndrome in humans (Patino et al., 2009) . Before the present study, all reported SCN1B mutations associated with human epilepsy were found to be located in the Ig domain that is shared between ␤1 and ␤1B. These results suggest that cell adhesion is clinically relevant and, importantly, that disruption of either splice variant may result in human brain disease. Novel evidence provided here demonstrates that ␤1B p.G257R (located in the retained intronic region unique to ␤1B) may be a risk factor for human epilepsy, suggesting that ␤1B is a critical player in brain development.
CAMs are critical for normal nervous system development and for synaptic plasticity in adulthood. Dysregulation of neural cell adhesion molecule (NCAM) expression or signaling is associated with a number of brain disorders, including depression, anxiety, bipolar disorder, and schizophrenia (for review, see Brennaman and Maness, 2010) . Deletion of Nr-CAM (neuronal cell adhesion molecule) in mice results in an altered behavioral phenotype reflective of increased impulsivity (Matzel et al., 2008) . Deletion of the CAM Lsamp in mice leads to heightened reactivity to novelty (Catania et al., 2008) and conditional deletion of L1-CAM in brain results in decreased anxiety-like behavior (Law et al., 2003) . Epilepsy and neuropsychiatric disease have a bidirectional relationship of comorbidity (Dixon-Salazar et al., 2004; Gargus, 2006; Jacoby and Thapar, 2009; Pauli and Stefan, 2009; Spence and Schneider, 2009 ) and thus may share common genetic mechanisms. SCN1B-dependent regulation of neuronal pathfinding may be critical to abnormal brain development in both neurological and psychiatric disease. Expression of multiple SCN1B splice variants, including a secreted form, is also consistent with other members of the Ig superfamily of CAMs (Rougon and Hobert, 2003; Jones et al., 2009 ). For example, increased expression of secreted forms of NCAM is associated with bipolar disorder and depression (Brennaman and Maness, 2010) . In a similar way, modulation of ␤1B secretion may have pathological consequences in brain, as suggested here for ␤1B p.G257R.
We did not detect biochemical association of human ␤1B with human Na v 1.1, Na v 1.3, or Na v 1.5. Despite this, coexpression of Na v 1.3 and ␤1B revealed subtle changes in Na ϩ current, similar to our previously published results with rat ␤1B and Na v 1.2 , suggesting that ␤1B may associate weakly or transiently with VGSC ␣-subunits and play a minor current modulatory role in brain. We observed that ␤1B was sequestered at the cell surface by Na v 1.5 but not by Na v 1.1 or Na v 1.3. Thus, the association between ␤1B and Na v 1.5 may be stronger than between ␤1B and the tetrodotoxin-sensitive channels, in agreement with a previous study showing modulation of Na v 1.5 current density in heterologous cells by ␤1B and that a SCN1B mutation linked to Brugada syndrome disrupts the Na ϩ current modulatory properties of ␤1B (Watanabe et al., 2008) . In addition to heart, Na v 1.5 is expressed in a population of limbic neurons in brain (Hartmann et al., 1999) . Differential ␤1B expression in specific brain areas may result in diverse effects on excitability and neurite outgrowth depending on which VGSC ␣-subunits are coexpressed or perhaps upregulated in response to pathology (Waxman, 2006) . These data, in concert with our recent results showing specific partnering of Na v 1.6 and ␤1-subunits in cerebellum (Brackenbury et al., 2010) , raise the possibility that certain VGSC ␣-and ␤-subunits form selective partnerships in excitable cells.
SCN1B p.G257R results in intracellular retention of ␤1B, generating a functional null cellular phenotype. This mechanism is consistent with that of p.R125C, linked to Dravet syndrome, which results in intracellular retention of ␤1 and, presumably, ␤1B as well (Patino et al., 2009) . Despite this commonality, we demonstrate here that p.C121W and p.R85H are normally trafficked in heterologous cells, suggesting that intracellular retention is not a shared mechanism of SCN1B epilepsy mutations. These results agree with our previous results in heterologous cells (Meadows et al., 2002b) , but contrast with ␤1(C121W) knock-in mice, in which p.C121W appears to be retained inside the neuron (Wimmer et al., 2010) . Trafficking of this mutant subunit may differ in brain neurons compared with transfected fibroblasts. Alternatively, p.C121W may be transiently trafficked to the cell surface in both cell types, but then rapidly endocytosed due to protein misfolding or lack of cell-adhesive properties (Meadows et al., 2002b) .
For p.R125C and p.G257R, retention of these subunits in the cytoplasm may inhibit signaling or trafficking of other proteins or induce cellular stress leading to neural degeneration. Thus, SCN1B gene dosage may be critical for brain disease. Heterozygous expression of one mutant and one wild-type SCN1B allele results in mild to moderate GEFSϩ spectrum disorders with incomplete penetrance in human patients, with symptom severity likely depending on genetic background and/or epigenetic factors. In this sense, the pedigrees presented in our study are similar to those reported previously Watanabe et al., 2008) . In contrast, inheritance of two mutant SCN1B alleles affecting the region common to ␤1 and ␤1B and resulting in intracellular retention causes Dravet syndrome, the most severe, and sometimes fatal, disorder of the GEFSϩ spectrum (Patino et al., 2009 ). If, as predicted by the present data, secreted ␤1B regulates neurite extension in developing human brain through celladhesive interactions, gene dosage will be critically important, as varying levels of SCN1B expression are predicted to regulate gradients of ␤1B in the extracellular matrix, which may then serve as attractive or repulsive signals. The contribution of ␤1B to brain development is not yet known; however, our results shed new light on the role of this subunit in SCN1B function and present a fresh perspective on the biology of these multifunctional subunits.
